A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
Stopped Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.
Conditions
- Lupus Nephritis
- Systemic Lupus Erythematosus
Interventions
- DRUG: Corticosteroids
- DRUG: Cyclophosphamide
- DRUG: Mycophenolate Mofetil
- DRUG: Ocrelizumab
- DRUG: Placebo
- DRUG: Azathioprine
Sponsor
Genentech, Inc.
Collaborators